The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Probiotic normalization of Candida albicans in schizophrenia: A randomized, placebo-controlled, longitudinal pilot study
Open accessAbstract
The molecules and pathways of the gut-brain axis represent new targets for developing methods to diagnose and treat psychiatric disorders. Manipulation of the gut microbiome with probiotics may be a therapeutic strategy with the potential to relieve gastrointestinal (GI) comorbidities and improve psychiatric symptoms. Candida albicans and Saccharomyces cerevisiae, commensal yeast species, can be imbalanced in the unhealthy human microbiome, and these fungal exposures were previously found elevated in schizophrenia. In a longitudinal, double-blind, placebo-controlled, pilot investigation of 56 outpatients with schizophrenia, we examined the impact of probiotic treatment on yeast antibody levels, and the relationship between treatment and antibody levels on bowel discomfort and psychiatric symptoms. We found that probiotic treatment significantly reduced C. albicans antibodies over the 14-week study period in males, but not in females. Antibody levels of S. cerevisiae were not altered in either treatment group. The highest levels of bowel discomfort over time occurred in C. albicans-seropositive males receiving the placebo. We observed trends toward improvement in positive psychiatric symptoms in males treated with probiotics who were seronegative for C. albicans. Results from this pilot study hint at an association of C. albicans seropositivity with worse positive psychiatric symptoms, which was confirmed in a larger cohort of 384 males with schizophrenia. In conclusion, the administration of probiotics may help normalize C. albicans antibody levels and C. albicans-associated gut discomfort in many male individuals. Studies with larger sample sizes are warranted to address the role of probiotics in correcting C. albicans-associated psychiatric symptoms. ClinicalTrials.gov identifier: NCT01242371
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Characterization of the oral fungal microbiome (mycobiome) in healthy individuals
Ghannoum, M. A., Jurevic, R. J., Mukherjee, P. K., Cui, F., Sikaroodi, M., Naqvi, A., & Gillevet, P. M. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000713 · Cited by 1,150
Severance, E. G., Gressitt, K. L., Stallings, C. R., Origoni, A. E., Khushalani, S., Leweke, F. M., Dickerson, F. B., & Yolken, R. H. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.05.018 · Cited by 243
Self-citationMatsubara, V. H., Wang, Y., Bandara, H. M. H. N., Mayer, M. P. A., & Samaranayake, L. P. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7527-3 · Cited by 206
Dickerson, F. B., Stallings, C., Origoni, A., Katsafanas, E., Savage, C. L. G., Schweinfurth, L. A. B., Goga, J., Khushalani, S., & Yolken, R. H. (2014) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.13m01579 · Cited by 166
Self-citation
Cited by
Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00018.2018 · Cited by 5,286
A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders
Sorboni, S. G., Moghaddam, H. S., Jafarzadeh-Esfehani, R., & Soleimanpour, S. (2022) · Clinical Microbiology Reviews · doi:10.1128/cmr.00338-20 · Cited by 522
McGuinness, A. J., Davis, J. A., Dawson, S. L., Loughman, A., Collier, F., O’Hely, M., Simpson, C. A., Green, J., Marx, W., Hair, C., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01456-3 · Cited by 502
Microbiota-Gut-Brain Axis: New Therapeutic Opportunities
Long-Smith, C., O'Riordan, K. J., Clarke, G., Stanton, C., Dinan, T. G., & Cryan, J. F. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023628 · Cited by 419
Probiotics and the microbiota-gut-brain axis: Focus on psychiatry
Mörkl, S., Butler, M. I., Holl, A., Cryan, J. F., & Dinan, T. G. (2020) · Current Nutrition Reports · doi:10.1007/s13668-020-00313-5 · Cited by 337
The microbiome, immunity, and schizophrenia and bipolar disorder.
Dickerson, F., Severance, E., & Yolken, R. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.12.010 · Cited by 268
Self-citationCross talk: the microbiota and neurodevelopmental disorders
Kelly, J. R., Minuto, C., Cryan, J. F., Clarke, G., & Dinan, T. G. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00490 · Cited by 271
Microbiome, inflammation, epigenetic alterations, and mental diseases
Alam, R., Abdolmaleky, H. M., & Zhou, J. (2017) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32567 · Cited by 240
“Another randomized, placebo-controlled study reported a trend toward the improvement of positive psychiatric symptoms following 14 weeks probiotic treatment in male SCZ patients who were seronegative for Candida albicans (Severance et al., 2017).”
BackgroundAltered gut microbiota and mucosal immunity in patients with schizophrenia
Xu, R., Wu, B., Liang, J., He, F., Gu, W., Li, K., Luo, Y., Chen, J., Gao, Y., Wu, Z., et al. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.06.039 · Cited by 198
Autoimmune Diseases and Psychotic Disorders
Jeppesen, R., & Benros, M. E. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00131 · Cited by 165
Hungin, A. P. S., Mitchell, C. R., Whorwell, P., Mulligan, C., Cole, O., Agréus, L., Fracasso, P., Lionis, C., Mendive, J., Philippart de Foy, J. ‐., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14539 · Cited by 154
Okubo, R., Koga, M., Katsumata, N., Odamaki, T., Matsuyama, S., Oka, M., Narita, H., Hashimoto, N., Kusumi, I., Xiao, J., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.11.011 · Cited by 149
The connection between microbiome and schizophrenia
Golofast, B., & Vales, K. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.12.011 · Cited by 92
A Systematic Review of the Effect of Probiotic Supplementation on Schizophrenia Symptoms
Ng, Q. X., Soh, A. Y. S., Venkatanarayanan, N., Ho, C. Y. X., Lim, D. Y., & Yeo, W.-S. (2019) · Neuropsychobiology · doi:10.1159/000498862 · Cited by 87
Sex Differences in the Gut-Brain Axis: Implications for Mental Health
Holingue, C., Budavari, A. C., Rodriguez, K. M., Zisman, C. R., Windheim, G., & Fallin, M. D. (2020) · Current Psychiatry Reports · doi:10.1007/s11920-020-01202-y · Cited by 85
Le Morvan de Sequeira, C., Hengstberger, C., Enck, P., & Mack, I. (2022) · Nutrients · doi:10.3390/nu14030621 · Cited by 82
Gut microbial changes of patients with psychotic and affective disorders: A systematic review
Vindegaard, N., Speyer, H., Nordentoft, M., Rasmussen, S., & Benros, M. E. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2019.12.014 · Cited by 66
Metagenomic symphony of the intestinal ecosystem: How the composition affects the mind
Malan-Müller, S., Martín-Hernández, D., Caso, J. R., Matthijnssens, J., Rodríguez-Urrutia, A., Lowry, C. A., & Leza, J. C. (2025) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2024.09.033 · Cited by 24
Metadata
- Authors
- Severance, E. G., Gressitt, K. L., Stallings, C. R., Katsafanas, E., Schweinfurth, L. A., Savage, C. L. G., Adamos, M. B., Sweeney, K. M., Origoni, A. E., Khushalani, S., Dickerson, F. B., & Yolken, R. H.
- Venue
- Brain, Behavior, and Immunity
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 62
- Pages
- 41-45
- ISSN
- 0889-1591 (ISSN-L)
- OpenAlex
- W2553126642
- Cited by
- 165
- References
- 5
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.